Cargando…

Cardiovascular outcomes and safety with linagliptin, a dipeptidyl peptidase‐4 inhibitor, compared with the sulphonylurea glimepiride in older people with type 2 diabetes: A subgroup analysis of the randomized CAROLINA trial

AIM: To compare the cardiovascular (CV) safety of linagliptin with glimepiride in older and younger participants in the CAROLINA trial in both prespecified and post hoc analyses. MATERIALS AND METHODS: People aged 40 to 85 years with relatively early type 2 diabetes, inadequate glycaemic control and...

Descripción completa

Detalles Bibliográficos
Autores principales:	Espeland, Mark A., Pratley, Richard E., Rosenstock, Julio, Kadowaki, Takashi, Seino, Yutaka, Zinman, Bernard, Marx, Nikolaus, McGuire, Darren K., Andersen, Knut Robert, Mattheus, Michaela, Keller, Annett, Weber, Maria, Johansen, Odd Erik
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Blackwell Publishing Ltd 2020
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7839453/ https://www.ncbi.nlm.nih.gov/pubmed/33185002 http://dx.doi.org/10.1111/dom.14254

Ejemplares similares

Design and baseline characteristics of the CARdiovascular Outcome Trial of LINAgliptin Versus Glimepiride in Type 2 Diabetes (CAROLINA(®))
por: Marx, Nikolaus, et al.
Publicado: (2015)

Rationale and design of the CAROLINA® - cognition substudy: a randomised controlled trial on cognitive outcomes of linagliptin versus glimepiride in patients with type 2 diabetes mellitus
por: Biessels, Geert Jan, et al.
Publicado: (2018)

Effects of linagliptin vs glimepiride on cognitive performance in type 2 diabetes: results of the randomised double-blind, active-controlled CAROLINA-COGNITION study
por: Biessels, Geert Jan, et al.
Publicado: (2021)

Postprandial renal haemodynamic effects of the dipeptidyl peptidase‐4 inhibitor linagliptin versus the sulphonylurea glimepiride in adults with type 2 diabetes (RENALIS): A predefined substudy of a randomized, double‐blind trial
por: Muskiet, Marcel H. A., et al.
Publicado: (2021)

Effects of dipeptidyl peptidase‐4 inhibitor linagliptin versus sulphonylurea glimepiride on systemic haemodynamics in overweight patients with type 2 diabetes: A secondary analysis of an 8‐week, randomized, controlled, double‐blind trial
por: Kraaijenhof, Jordan, et al.
Publicado: (2020)

Dipeptidyl Peptidase-4 Inhibitors for the Potential Treatment of Brain Disorders; A Mini-Review With Special Focus on Linagliptin and Stroke
por: Darsalia, Vladimer, et al.
Publicado: (2019)

The role of renal dipeptidyl peptidase-4 in kidney disease: renal effects of dipeptidyl peptidase-4 inhibitors with a focus on linagliptin
por: Kanasaki, Keizo
Publicado: (2018)

Addition of dipeptidyl peptidase-4 inhibitors to sulphonylureas and risk of hypoglycaemia: systematic review and meta-analysis
por: Salvo, Francesco, et al.
Publicado: (2016)

Linagliptin—A Novel Dipeptidyl Peptidase Inhibitor for Type 2 Diabetes Therapy
por: Gallwitz, Baptist
Publicado: (2012)

Correction: The role of renal dipeptidyl peptidase-4 in kidney disease: renal effects of dipeptidyl peptidase-4 inhibitors with a focus on linagliptin
por: Kanasaki, Keizo
Publicado: (2019)

SUN-LB015 Baseline Characteristics and Effects on CV and Kidney Outcomes with Linagliptin Versus Placebo, Across GFR Categories in CARMELINA
por: Kahn, Steven, et al.
Publicado: (2019)

Dipeptidyl peptidase-4 inhibitor linagliptin attenuates neointima formation after vascular injury
por: Terawaki, Yuichi, et al.
Publicado: (2014)

Cardiovascular and kidney outcomes of linagliptin treatment in older people with type 2 diabetes and established cardiovascular disease and/or kidney disease: A prespecified subgroup analysis of the randomized, placebo‐controlled CARMELINA® trial
por: Cooper, Mark E., et al.
Publicado: (2020)

Efficacy of dipeptidyl peptidase-4 inhibitor linagliptin in patients with type 2 diabetes undergoing hemodialysis
por: Terawaki, Yuichi, et al.
Publicado: (2015)

Linagliptin, A Xanthine-Based Dipeptidyl Peptidase-4 Inhibitor, Ameliorates Experimental Autoimmune Myocarditis
por: Shiheido-Watanabe, Yuka, et al.
Publicado: (2021)

HbA(1c), Insulin Resistance, and β-Cell Function in Relation to Cognitive Function in Type 2 Diabetes: The CAROLINA Cognition Substudy
por: Janssen, Jolien, et al.
Publicado: (2019)

Effects of Linagliptin on Cardiovascular and Kidney Outcomes in People With Normal and Reduced Kidney Function: Secondary Analysis of the CARMELINA Randomized Trial
por: Perkovic, Vlado, et al.
Publicado: (2020)

Effect of linagliptin versus placebo on cardiovascular and kidney outcomes in nephrotic-range proteinuria and type 2 diabetes: the CARMELINA randomized controlled trial
por: Wanner, Christoph, et al.
Publicado: (2021)

Dipeptidyl peptidase-4 inhibition with linagliptin prevents western diet-induced vascular abnormalities in female mice
por: Manrique, Camila, et al.
Publicado: (2016)

Linagliptin, a Selective Dipeptidyl Peptidase-4 Inhibitor, Reduces Physical and Behavioral Effects of Morphine Withdrawal
por: Listos, Joanna, et al.
Publicado: (2022)

Erratum to: Effect of linagliptin versus placebo on cardiovascular and kidney outcomes in nephrotic-range proteinuria and type 2 diabetes (t2d): the carmelina randomised controlled trial
por: Wanner, Christoph, et al.
Publicado: (2021)

Review of the cardiovascular safety of dipeptidyl peptidase-4 inhibitors and the clinical relevance of the CAROLINA trial
por: Santamarina, Marile, et al.
Publicado: (2019)

The Dipeptidyl Peptidase-4 Inhibitor Linagliptin Ameliorates High-fat Induced Cognitive Decline in Tauopathy Model Mice
por: Nakaoku, Yuriko, et al.
Publicado: (2019)

The Dipeptidyl Peptidase-4 Inhibitor Linagliptin Ameliorates Endothelial Inflammation and Microvascular Thrombosis in a Sepsis Mouse Model
por: Wang, Shen-Chih, et al.
Publicado: (2022)

Modern sulphonylureas and cardiovascular adverse effects: Will CAROLINA put an end to the controversy?
por: John, Mathew, et al.
Publicado: (2020)

Cardiovascular safety of linagliptin in type 2 diabetes: a comprehensive patient-level pooled analysis of prospectively adjudicated cardiovascular events
por: Rosenstock, Julio, et al.
Publicado: (2015)

CARdiovascular Outcome study of LINAgliptin versus glimepiride in patients with T2D trial
por: Nath, Baishali, et al.
Publicado: (2020)

Effect of Switching from Linagliptin to Teneligliptin Dipeptidyl Peptidase-4 Inhibitors in Older Patients with Type 2 Diabetes Mellitus
por: Han, Eugene, et al.
Publicado: (2020)

Hemodynamic effects of the dipeptidyl peptidase-4 inhibitor linagliptin with renin–angiotensin system inhibitors in type 2 diabetic patients with albuminuria
por: Cooper, Mark E., et al.
Publicado: (2019)

Cardiovascular safety of Glimepiride: An indirect comparison from CAROLINA and CARMELINA
por: Ghosh, Sujoy, et al.
Publicado: (2020)

New insights into the role of dipeptidyl peptidase 8 and dipeptidyl peptidase 9 and their inhibitors
por: Cui, Chenkai, et al.
Publicado: (2022)

Dipeptidyl peptidase‐4 inhibitors and sulfonylureas for type 2 diabetes: Friend or foe?
por: Yabe, Daisuke, et al.
Publicado: (2014)

The dipeptidyl peptidase-4 inhibitor, linagliptin, improves cognitive impairment in streptozotocin-induced diabetic mice by inhibiting oxidative stress and microglial activation
por: Ide, Makoto, et al.
Publicado: (2020)

Dipeptidyl peptidase‐4 inhibitors and prevention of bone fractures: Effects beyond glyemic control
por: Yabe, Daisuke, et al.
Publicado: (2012)

Rationale, design, and baseline characteristics of the CArdiovascular safety and Renal Microvascular outcomE study with LINAgliptin (CARMELINA(®)): a randomized, double-blind, placebo-controlled clinical trial in patients with type 2 diabetes and high cardio-renal risk
por: Rosenstock, Julio, et al.
Publicado: (2018)

Preferential prescribing and utilization trends of diabetes medications among patients with renal impairment: Emerging role of linagliptin and other dipeptidyl peptidase 4 inhibitors
por: Patorno, Elisabetta, et al.
Publicado: (2017)

The Dipeptidyl Peptidase-4 Inhibitor Linagliptin Directly Enhances the Contractile Recovery of Mouse Hearts at a Concentration Equivalent to that Achieved with Standard Dosing in Humans
por: Batchu, Sri Nagarjun, et al.
Publicado: (2020)

A Single Second Shell Amino Acid Determines Affinity and Kinetics of Linagliptin Binding to Type 4 Dipeptidyl Peptidase and Fibroblast Activation Protein
por: Schnapp, Gisela, et al.
Publicado: (2020)

Linagliptin use in older individuals with type 2 diabetes
por: Pratley, Richard E
Publicado: (2014)

The DPP-4 Inhibitor Linagliptin Counteracts Stroke in the Normal and Diabetic Mouse Brain: A Comparison With Glimepiride
por: Darsalia, Vladimer, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_t7s1l2djmt4c74m3es3nvsuah2